Results 131 to 140 of about 15,205 (209)

Vascular Endothelial Effects of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction: Randomized Controlled Trial [PDF]

BACKGROUND The mechanism of how sacubitril/valsartan improves outcomes in heart failure with reduced ejection fraction (HFrEF) is still incompletely understood.
Barthelmes, Jens, Flammer, Andreas J, Haider, Thomas, Hebeisen, Monika, Kreysing, Leonie, Nebunu, Delia, Nägele, Matthias P, Rossi, Valentina A, Ruschitzka, Frank, Sudano, Isabella   +9 more
core   +1 more source

The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey [PDF]

, 2017
Bateman, Randy J, et al,
core   +2 more sources

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)

The Journal of Clinical Hypertension
Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials.
Koichi Yamamoto, Daisuke Yarimizu, Ayano Shimanishi, Shunsuke Eguchi, Kazuma Iekushi, Yoichi Takami, Yoichi Nozato, Kazuomi Kario, Hiromi Rakugi   +8 more
doaj   +1 more source

Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure [PDF]

, 2021
Shehar Bano, Pooja Bai, Sameet Kumar, Nomesh Kumar, Ahmed Ali, Fnu Pariya, Fnu Versha, Dua Khalid, Haya Khalid, Amber Rizwan   +9 more
openalex   +1 more source

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction

Frontiers in Pharmacology
Background and aim:Heart failure with preserved ejection fraction (HFpEF) is associated with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD).
Ronen Arbel, Abed N. Azab, Abed N. Azab, Mansi Oberoi, Enis Aboalhasan, Artyom Star, Khaled Elhaj, Fouad Khalil, Hilmi Alnsasra, Hilmi Alnsasra   +9 more
doaj   +1 more source

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure [PDF]

, 2019
Scott D. Solomon, Muthiah Vaduganathan, Brian Claggett, Milton Packer, Michael R. Zile, Karl Swedberg, Jean L. Rouleau, Marc A. Pfeffer, Akshay S. Desai, Lars H. Lund, Lars Køber, Inder S. Anand, Nancy K. Sweitzer, Gerard C.M. Linssen, Béla Merkely, Juan Luis Arango, Dragoş Vinereanu, Chen-Huan Chen, Michele Senni, Antonio S. Sibulo, S. А. Boytsov, Victor Shi, Adel R. Rizkala, Martin Lefkowitz, John J.V. McMurray   +24 more
openalex   +1 more source

Correction to ‘Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting’

ESC Heart Failure, Volume 12, Issue 2, Page 1525-1525, April 2025.
wiley   +1 more source

Subgroup disproportionality analysis of dementia-related adverse events with sacubitril/valsartan across geographical regions

Scientific Reports
This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis.
Seong Kyung Kim, Myeong Gyu Kim
doaj   +1 more source

Sacubitril-Valsartan in Patients Requiring Hemodialysis [PDF]

Dustin Le, Morgan E. Grams, Josef Coresh, Jung‐Im Shin   +3 more
openalex   +1 more source

PROTECTIVE EFFECTS OF ULTRASOUND-BASED PREOPERATIVE EXOGENOUS SACUBITRIL/VALSARTAN ON THE HEART AND KIDNEY OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [PDF]

, 2023
YUNFEI WANG
openalex   +1 more source